Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Whether KRAS-mutant NSCLCs should be excluded from pemetrexed-containing regimens should be assessed prospectively.
|
31332704 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The inhibition of miR-199b stimulated NSCLC growth and metastasis, while restoration of miR-199b suppressed K-Ras mutation-driven lung tumorigenesis as well as K-Ras-mutated NSCLC growth and metastasis. miR-199b inactivated ERK and Akt pathways by targeting K-Ras, KSR2, PIK3R1, Akt1, and Rheb1.
|
30987652 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
|
30599853 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study supports the importance of accurate patient stratification and rational drug combinations to gain benefit from MEK inhibition in patients with KRAS mutant NSCLC.
|
31668570 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition to testing common driving genes, like EGFR, ALK, ROS1 and BRAF, both TP53, and KRAS should also be considered in advanced or metastatic squamous-cell NSCLC.TP53 and KRAS co-mutations in squamous-cell NSCLC can be a potential factor to assess possible response to PD-1 blockade immunotherapy, but further studies with more cases are needed to confirm the prediction power.
|
31619231 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This review will discuss the most recent findings on mutant KRAS metabolic reliance in tumor models of pancreatic and non-small-cell lung cancer, also highlighting the role that these metabolic adaptations play in resistance to target therapy.
|
31544066 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of EGFR Mutation status for the administration of EGFR-TKIs in non-small cell lung Carcinoma (ERMETIC) was a prospective study designed to validate the prognostic value of EGFR/KRAS mutations in patients with advanced non-small-cell lung cancer (NSCLC), all receiving a first-generation tyrosine kinase inhibitor, erlotinib.
|
30679079 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations.
|
30377342 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Pretreatment with RAD001 (0.1 nmol/L) enhanced the radiosensitivity in NCI-H661 cells with wild-type PIK3CA and KRAS but not in NCI-H460 cells with mutant PIK3CA and KRAS; the sensitivity enhancement ratios in the two NSCLC cell lines were 1.40 and 1.03, respectively.
|
30796356 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53, EGFR and KRAS mutations are associated with expression of glucose and glutamine metabolism-related markers in NSCLC.
|
31668020 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
With signs of real progress in this subgroup of unmet need, we anticipate that KRAS mutant NSCLC will be the most important molecular subset of cancer to evaluate the combination of small molecules and immune checkpoint inhibitors (CPI).
|
30852159 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Compared with EGFR and KRAS wild type, in NSCLC tissue with EGFR and KRAS mutations, the expression of AKT and p-AKT was significantly higher.
|
28043144 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings demonstrate that the miR-148a-3p may play a significant role in NSCLC including the kind of lung cancer with K-Ras gene mutation, and it exerted the tumor inhibitor function by targeting SOS2.
|
30536836 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The destabilization of Ras via inhibition of the Wnt/β-catenin pathway is a potential therapeutic strategy for KRAS-mutated NSCLC that is resistant to EGFR TKI.
|
30679620 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, OS was longer for patients with TP53 and KRAS wild-type NSCLC who received chemotherapy for any stage compared with patients with KRAS, TP53 mutation, or double mutant tumors.
|
30770327 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The association of PD-L1 expression with KRAS mutations may have clinical relevance in selecting patients with NSCLC for immunotherapy.
|
31025831 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer.
|
30906631 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation.
|
30995478 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo studies demonstrated that NHTD suppressed proliferation, induced apoptosis and inhibited oncogenic K-RAS signaling pathways by disrupting KRAS-PDEδ interaction in nonsmall cell lung cancer (NSCLC) harboring KRAS mutations.
|
30786019 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To demonstrate Spa-RQ's applicability, we analysed the spatial aspects of oncogenic KRAS-related signalling activities in non-small cell lung cancer (NSCLC).
|
31772293 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
|
31521695 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
|
31798692 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in KRAS are detected in 30% of NSCLC cases, with most of them occurring in codons 12 and 13 and less commonly in others.
|
30862488 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, altogether our data provide new insights into proteome regulations in the context of overcoming the NSCLC resistance to gefitinib through KDACi in H358 KRAS mutated and amphiregulin-overexpressing NSCLC cells.
|
30660770 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a proof of concept, we applied this approach to a KRAS-dependent non-small cell lung cancer (NSCLC) cell line, H23-KRAS<sup>G12C</sup> Using a combination of phenotypic screens, signaling analyses, and kinase inhibitors, we found that dual inhibition of MEK1/2 and insulin-like growth factor 1 receptor (IGF1R)/insulin receptor (INSR) is critical for blocking proliferation in cells.
|
30858179 |
2019 |